Connect with us

Health

New drug shows potential to cure and prevent malaria

Published

on

New York: A drug currently being tested on humans shows potential to cure malaria in a single dose and offers promise as a preventive treatment as well, new research says.

The compound, invented by an international team of researchers, including Indian-origin Pradipsinh Rathod from the University of Washington, is the first to cripple a critical protein that the malaria parasite needs to survive at different stages of its complex life cycle, the study noted.

“This is the first of a new class of molecules that is going into humans,” said professor Rathod, one of the founders and leaders of this endeavour.

The new drug — DSM265 — kills drug-resistant malaria parasites in the blood and liver by targeting their ability to replicate.

Malaria is a highly infectious, mosquito-transmitted disease that kills nearly 600,000 people worldwide each year. Nearly 200 million cases of malaria are reported annually, and about three billion people are at risk of malaria in 97 countries.

“DSM265 could be among the first single-dose cures for malaria, and would be used in partnership with another drug,” lead author Margaret Phillips, professor of pharmacology at the University of Texas Southwestern Medical Centre in the US, said.

The study was published in the journal Science Translational Medicine.

Researchers determined that the compound DSM265 kills the malaria parasite Plasmodium in both liver and blood stages of infection. Further, the compound was shown to be well tolerated and effective in preclinical models.

Currently, the front-line anti-malarial treatments are artemisinin-based combination therapies, or ACTs, which are credited with helping to reduce the malaria burden.

However, malaria strains resistant to ACTs have recently been reported in Thailand, Cambodia, Vietnam, Myanmar, and Laos.

In order to combat drug resistance, DSM265 would likely be partnered with another new drug and used as a one-dose combination therapy.

The study concluded that DSM265 appeared to be safely tolerated in non-human tests and established optimal dosing levels and length of drug effectiveness in preclinical models to estimate dosing for humans, paving the way for clinical trials.

The first clinical trial was a safety study in Australia, followed by an ongoing efficacy study in Peru to evaluate the ability to treat patients with malaria.

Additional human studies are planned, including one to test the drug as a preventive medicine, the study noted.

Corona

Covid toll in Karnataka is a worrying sign for state government

Published

on

 

Even though Karnataka recorded the lowest number of Covid deaths in April since the virus struck first in 2020, the state is recording a rise in the positivity rate (1.50 per cent). Five people died from the Covid infections in April as per the statistics released by the state health department. In March, the positivity rate stood around 0.53 per cent. In the first week of April it came down to 0.38 per cent, second week registered 0.56 per cent, third week it rose to 0.79 per cent and by end of April the Covid positivity rate touched 1.19 per cent.

on an average 500 persons used to succumb everyday in the peak of Covid infection, as per the data. Health experts said that the mutated Coronavirus is losing its fierce characteristics as vaccination, better treatment facilities and awareness among the people have contributed to the lesser number of Covid deaths.

During the 4th and 6th of April two deaths were reported in Bengaluru, one in Gadag district on April 8, two deaths were reported from Belagavi and Vijayapura on April 30. The first Covid case was reported in the state in March 2020 and three Covid deaths were recorded in the month. In the following month 21 people became victims to the deadly virus, and May 2020 recorded 22 deaths. The death toll recorded everyday after May crossed three digits. However, the third wave, which started in January 2

Continue Reading

Trending